Adaptimmune Therapeutics (NASDAQ:ADAP) Trading Down 5.3%

Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s stock price was down 5.3% on Wednesday . The company traded as low as $1.08 and last traded at $1.08. Approximately 126,750 shares changed hands during trading, a decline of 93% from the average daily volume of 1,761,175 shares. The stock had previously closed at $1.14.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Adaptimmune Therapeutics in a research report on Friday, December 29th. They set a “hold” rating for the company.

Adaptimmune Therapeutics Trading Down 1.9 %

The company has a market cap of $1.05 billion, a price-to-earnings ratio of -1.93 and a beta of 2.39. The firm’s 50-day moving average price is $1.39 and its 200 day moving average price is $0.93.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.12). The company had revenue of $0.23 million for the quarter, compared to analyst estimates of $4.80 million. Adaptimmune Therapeutics had a negative return on equity of 155.39% and a negative net margin of 188.90%. Analysts forecast that Adaptimmune Therapeutics plc will post -0.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

A number of large investors have recently modified their holdings of the company. Harbor Capital Advisors Inc. lifted its holdings in shares of Adaptimmune Therapeutics by 9.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 13,317 shares in the last quarter. Columbia Advisory Partners LLC bought a new position in shares of Adaptimmune Therapeutics in the 1st quarter worth $25,000. Key Client Fiduciary Advisors LLC lifted its holdings in shares of Adaptimmune Therapeutics by 6.4% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 20,295 shares in the last quarter. JTC Employer Solutions Trustee Ltd bought a new position in shares of Adaptimmune Therapeutics in the 1st quarter worth $41,000. Finally, Barclays PLC bought a new position in shares of Adaptimmune Therapeutics in the 2nd quarter worth $46,000. 31.37% of the stock is currently owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.